English appeals court refuses Neurim injunction for insomnia drug

The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Neurim, Flynn discover that time is not on their side

26 May 2022 The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.

Big Pharma

English High Court denies Mylan a stay in Neurim litigation

2 November 2021 Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court.

Americas

Neurim prevails against Mylan in suit over insomnia drug

8 December 2020 Neurim Pharmaceuticals has won its case against generics drug maker Mylan at the English High Court, which held that its patent for a treatment for insomnia was valid and had been infringed in a ruling handed down on December 4.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

English appeals court refuses Neurim injunction for insomnia drug

More on this story

Editor's picks

Editor's picks

More features